These results reveal that the MAZ/MAP2K2/ERK signaling axis plays a crucial role in promoting ccRCC progression, which suggests the potential therapeutic utility of MAZ in ccRCC. Here, MAP2K2 is linked to nonpapillary renal cell carcinoma.